Can we improve outcomes by changing treatment before radiographic progression occurs?In this in-depth discussion, Dr. Anne O'Dea and Dr. Mabel Mardones explore how the SERENA-6 trial is reshaping the management of HR-positive, HER2-negative metastatic breast cancer through ctDNA-guided treatment decisions and earlier intervention for emerging ESR1 mutations.Topics discussed include:The clinical impact of the SERENA-6 trialUsing ctDNA to detect ESR1 mutations before disease progressionWhen and why to switch endocrine therapyCamizestrant and molecularly guided treatment strategiesIntegrating biomarker monitoring into routine clinical practicePatient communication, monitoring, and quality-of-life considerationsPractical challenges and implementation in the community settingFeaturing expert insights from Dr. Anne O'Dea and Dr. Mabel Mardones on one of the most important advances in precision oncology for HR-positive metastatic breast cancer.Watch the full conversation and subscribe for more expert discussions on the latest clinical evidence shaping cancer care.

HER2-positive breast cancer treatment is evolving rapidly. With FDA approvals from DESTINY-Breast11 and DESTINY-Breast05, when should clinicians incorporate trastuzumab deruxtecan (T-DXd) into practice—and how should it be used across early-stage and into metastatic disease?In this in-depth discussion, Dr. Rena Callahan and Dr. Aditya Bardia explore how these landmark studies are changing treatment decisions today across neoadjuvant, adjuvant, and metastatic settings—including the management of residual disease and the optimization of first-line metastatic care.Key topics discussed:• How DESTINY-Breast11 is changing neoadjuvant treatment strategies• DESTINY-Breast05 and the role of T-DXd for residual disease• Which patients should receive T-DXd versus T-DM1• Managing ILD risk and monitoring requirements• Treatment decisions for patients who do not achieve pCR• Rechallenging T-DXd after recurrence• First-line metastatic HER2-positive breast cancer after DESTINY-Breast09• Deep responses, complete responses, and long-term outcomes• T-DXd versus THP in clinical practice• PATINA, HER2CLIMB-05, and evolving maintenance strategies• CNS metastases and the role of HER2-targeted ADCs• Treatment holidays, ctDNA monitoring, and personalized careAs T-DXd moves into earlier lines of therapy, oncologists are facing new questions around sequencing, toxicity management, and optimizing long-term outcomes. This conversation provides practical insights for both academic and community clinicians navigating this rapidly changing landscape.Subscribe for more expert oncology discussions, breast cancer updates, and clinical trial insights from Community Health Media.

The first-line treatment landscape for metastatic triple-negative breast cancer is changing rapidly.Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, and Dr. Ana Garrido-Castro discuss how ADCs are reshaping frontline TNBC care and what the latest clinical evidence means for real-world practice.The conversation explores:• The evolution of metastatic TNBC treatment• Why many patients never reach second-line therapy• The impact of ASCENT and sacituzumab govitecan• ASCENT-03 and ASCENT-04 trial results• TROPION-Breast02 and datopotamab deruxtecan• The role of crossover in interpreting overall survival• PFS, OS, and PFS2 as clinical trial endpoints• Selecting between SG and Dato-DXd• Managing neutropenia, stomatitis, ocular toxicity, and ILD• Shared decision-making in frontline TNBC• Why using the best therapy first may matter mostThis comprehensive discussion examines the evidence driving ADC use in metastatic TNBC and how clinicians can individualize treatment selection in an increasingly complex therapeutic landscape.Watch now to hear how ADCs are reshaping frontline TNBC care.